Actively Recruiting

Phase 3
Age: 18Years +
All Genders
Healthy Volunteers
ID07496450

A Phase 3, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of mRNA-1018-H5 Pandemic Influenza Vaccine in Adults 18 Years and Older

Led by ModernaTX, Inc. · Updated on 2026-04-03

4000

Participants Needed

36

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the immune response and safety of the mRNA-1018-H5 vaccine against pandemic influenza in healthy adults aged 18 years and older. The study aims to measure how well the vaccine triggers protective antibodies and to monitor any side effects or reactions. This is a phase 3 randomized trial sponsored by ModernaTX, Inc., focusing on adults without significant health issues or with stable chronic conditions. Participants will be randomly assigned to receive either the mRNA-1018-H5 vaccine or a placebo. Both are given as intramuscular injections on Day 1 and Day 22. The vaccine is a sterile liquid designed for injection. The study includes a blinded design to ensure unbiased safety and immunogenicity assessments. Participants may be monitored for up to 205 days to assess antibody levels and adverse events. During the study, participants will have blood tests to measure antibody responses on Days 22, 43, and 205. Researchers will track local and systemic reactions for 7 days after each injection and any adverse events for up to 205 days. The main outcomes include the percentage of participants achieving protective antibody levels, immune response strength, and safety measures. Participants will be involved in regular visits and evaluations throughout the study period.

CONDITIONS

Brief Title

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy adults aged 18 years or older as determined by medical evaluation
  • Participants with stable chronic medical conditions are allowed
  • Females assigned at birth or those who could become pregnant must not be pregnant or breastfeeding
  • Persons of childbearing potential must have a negative pregnancy test at screening and on Day 1
  • Persons of nonchildbearing potential are eligible
Not Eligible

You will not qualify if you...

  • Acutely ill or feverish (temperature ≥ 38.0°C/100.4°F) within 72 hours before screening or Day 1
  • History of myocarditis, pericarditis, or myopericarditis
  • History of Guillain-Barre syndrome
  • History of congenital or acquired immunodeficiency, immunosuppressive conditions, asplenia, or recurrent severe infections
  • Use of antiviral therapies for influenza within 28 days before Day 1
  • Prior receipt of any pandemic influenza vaccine or participation in related vaccine studies
  • Use of systemic immunosuppressants or long-acting biological therapies within 180 days prior to screening
  • Use of corticosteroids at ≥10 mg/day prednisone or equivalent for more than 14 days within 90 days before Day 1
  • Receipt of any licensed vaccine, including mRNA vaccines, within 28 days prior to Day 1 or planned vaccination within 21 days after study intervention
  • Participation in another interventional clinical study within 90 days prior to screening
  • Any medical, psychiatric, or occupational condition that may pose additional risk or interfere with study adherence or results

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

screening and enrollment visit

Treatment

Duration - Approximately 7 weeks

Participants receive two intramuscular injections of either the mRNA-1018-H5 vaccine or placebo on Day 1 and Day 22.

2 visits (Day 1 and Day 22 injections) and additional safety monitoring visits up to Day 50

Follow-up

Duration - Up to 6 months after last injection

Participants are monitored for safety and immunogenicity outcomes up to Day 205 after the last injection.

Visits at Days 43, 50, and 205 for immunogenicity and safety assessments

Trial Site Locations

Total: 36 locations

1

Velocity Clinical Research, San Bernardino

San Bernardino, California, United States, 92408

Not Yet Recruiting

2

Velocity Clinical Research, Savannah

Savannah, Georgia, United States, 31406

Not Yet Recruiting

3

Velocity Clinical Research, Boise

Meridian, Idaho, United States, 83642

Not Yet Recruiting

4

Velocity Clinical Research, Rockville

Rockville, Maryland, United States, 20854

Not Yet Recruiting

5

Velocity Clinical Research, Omaha

Omaha, Nebraska, United States, 68134

Not Yet Recruiting

6

Velocity Clinical Research, Cleveland

Beachwood, Ohio, United States, 44122

Actively Recruiting

7

Velocity Clinical Research, Providence

East Greenwich, Rhode Island, United States, 02818

Actively Recruiting

8

Velocity Clinical Research, Anderson

Anderson, South Carolina, United States, 29621

Not Yet Recruiting

9

Velocity Clinical Research, Dallas

Dallas, Texas, United States, 75230

Actively Recruiting

10

Velocity Clinical Research, Suffolk

Suffolk, Virginia, United States, 23435

Not Yet Recruiting

11

Velocity Clinical Research-Bristol

Bristol, Bristol (Unitary Authority), United Kingdom, BS8 2RA

Not Yet Recruiting

12

Velocity Clinical Research - High Wycombe

High Wycombe, Buckinghamshire, United Kingdom, HP11 2QW

Not Yet Recruiting

13

Wansford Research Ltd

Peterborough, Cambridgeshire, United Kingdom, PE8 6PL

Not Yet Recruiting

14

Futuremeds Teesside Middlefield Centre University Hospital of North Tees

Stockton-on-Tees, County Durham, United Kingdom, TS19 8PE

Not Yet Recruiting

15

NIHR Wessex CRDC - Bournemouth Research Hub (Under University Hospital Southampton NHS Foundation Trust)

Bournemouth, Dorset, United Kingdom, BH7 7DW

Not Yet Recruiting

16

NIHR Wessex CRDC - Weymouth Research Hub (Under University Hospital Southampton NHS Foundation Trust)

Weymouth, Dorset, United Kingdom, DT4 0QE

Not Yet Recruiting

17

Panthera Glasgow

Glasgow, Glasgow City (Scotland), United Kingdom, G51 4TF

Not Yet Recruiting

18

Panthera Enfield

Enfield, Greater London, United Kingdom, EN3 4GS

Not Yet Recruiting

19

Hounslow Medical Centre

Hounslow, Greater London, United Kingdom, TW3 3ET

Not Yet Recruiting

20

hVIVO Services Limited

London, Greater London, United Kingdom, E1 1EQ

Not Yet Recruiting

21

Velocity Clinical Research-North London

London, Greater London, United Kingdom, N12 8BU

Not Yet Recruiting

22

Accellacare North London

Northwood, Greater London, United Kingdom, HA6 2RN

Not Yet Recruiting

23

Accellacare South London

Orpington, Greater London, United Kingdom, BR5 3QG

Not Yet Recruiting

24

Velocity Clinical Research-Romford

Romford, Greater London, United Kingdom, RM1 3PJ

Not Yet Recruiting

25

Panthera Rochdale

Rochdale, Greater Manchester, United Kingdom, OL11 4AU

Not Yet Recruiting

26

NIHR Wessex CRDC - Southampton Research Hub (Under University Hospital Southampton NHS FT)

Southampton, Hampshire, United Kingdom, SO15 3UA

Not Yet Recruiting

27

Fylde Coast Clinical Research at Layton Medical Centre

Blackpool, Lancashire, United Kingdom, FY3 7EN

Not Yet Recruiting

28

FutureMeds Liverpool

Metropolitan Borough of Wirral, Merseyside, United Kingdom, CH62 6EE

Not Yet Recruiting

29

Lakeside Healthcare

Corby, North Northamptonshire, United Kingdom, NN17 2UR

Not Yet Recruiting

30

Panthera York

York, North Yorkshire, United Kingdom, YO24 4LJ

Not Yet Recruiting

31

The University of Nottingham Health Service

Nottingham, Nottinghamshire, United Kingdom, NG7 2QW

Not Yet Recruiting

32

Panthera Sheffield

Sheffield, South Yorkshire, United Kingdom, S2 5FX

Not Yet Recruiting

33

FutureMeds Newcastle

Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE61SG

Not Yet Recruiting

34

Accellacare Warwickshire

Coventry, West Midlands (Coventry), United Kingdom, CV3 4FJ

Not Yet Recruiting

35

FutureMeds Birmingham Soho Road Health Centre

Birmingham, West Midlands, United Kingdom, B21 9RY

Not Yet Recruiting

36

Accellacare Yorkshire

Shipley, West Yorkshire, United Kingdom, BD18 3SA

Not Yet Recruiting

Loading map...

Research Team

M

Moderna WeCare Team

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here